Health Care·Life Sciences Tools & Services·$6.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.06 | N/A | -100.00% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.06 | N/A | -100.00% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding future performance. They emphasized the need for operational improvements but did not offer specific targets.
Management did not provide specific guidance for future quarters.
The company is focused on maintaining operational efficiency.
Repligen Corp's earnings report indicates a challenging quarter, with a loss per share that surprised investors. The stock reacted negatively, dropping 2.53%. The lack of revenue details and guidance may contribute to investor uncertainty moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ABM INDS INC
Jun 7, 2011